## Why option 1 is correct Vancomycin is a large glycopeptide antibiotic (molecular weight ~1450 Da) that binds the D-alanyl-D-alanine terminal of peptidoglycan precursors, blocking cross-linking and cell wall synthesis. In Gram-positive bacteria, the thick peptidoglycan layer (marked **A**) is directly accessible to vancomycin. However, Gram-negative bacteria possess an outer membrane composed of lipopolysaccharide (LPS) and phospholipids. This outer membrane is impermeable to large hydrophilic molecules like vancomycin, preventing the drug from reaching the peptidoglycan layer in the periplasmic space. Thus, vancomycin is effective only against Gram-positive organisms. This is the fundamental pharmacological principle underlying vancomycin's spectrum of activity (Murray 9e; KD Tripathi 9e Ch 53). ## Why each distractor is wrong - **Option 2**: Vancomycin is not metabolized by bacterial enzymes; it is not a prodrug. LPS does not enzymatically inactivate vancomycin. This confuses drug metabolism with drug penetration. - **Option 3**: While some Gram-negative bacteria do possess efflux pumps, vancomycin's inability to cross the outer membrane is the primary reason for its lack of activity—the drug never reaches the cell interior to be pumped out. Efflux resistance is a secondary mechanism in organisms already permeable to the drug. - **Option 4**: The periplasmic space exists in Gram-negative bacteria (between the inner and outer membranes), not Gram-positive bacteria. Gram-positive bacteria lack an outer membrane entirely. This option reverses the anatomical fact. **High-Yield:** Vancomycin = large, hydrophilic, cannot cross Gram-negative outer membrane → Gram-positive only (MRSA, C. difficile, enterococcal endocarditis). [cite: Murray 9e; KD Tripathi 9e Ch 53]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.